Research programme: ketamine deuterated - Teva Pharmaceutical Industries

Drug Profile

Research programme: ketamine deuterated - Teva Pharmaceutical Industries

Alternative Names: Deuterium-containing ketamine - Teva Pharmaceutical Industries

Latest Information Update: 08 May 2015

Price : $50

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Teva Pharmaceutical Industries
  • Class Analgesics; Inorganic deuterium compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 18 Mar 2014 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top